1.Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; 6: 87-93.2.AstraZeneca Pharmaceuticals. Data on file. Budesonide/formoterol: Annual Rate of Exacerbations Globally (ID: SD-3010-ALL-0017).3.From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2020. 21.04.2020. http://www.ginasthma.org4.Asthma UK. www.asthma.org.uk/getinvolved/campaigns/data-visualisations/5.Price D, Fletcher M, van der Molen T Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24: 14009.6.Papi A, Ryan D, Soriano JB et al. Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract 2018; 6: 1989-98.e3.7.Partridge MR, van der Molen T, Myrseth SE et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6: 13.8.Schatz M, Zeiger RS, Vollmer WM et al. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117: 995-1000.9.Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604-10.10.Suissa S, Ernst P, Benayoun S et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-6.11.Reddel HK, FitzGerald JM, Bateman ED et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53 (6): 1901046.12.From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2020. 25.08.2020. http://www.ginasthma.org.13.Инструкция по медицинскому применению лекарственного препарата БУД/ФОРМ 80/4,5 мкг/доза, 160/4,5 мкг/доза (порошок для ингаляций дозированный) от 11.04.2019. Регистрационное удостоверение П N013167/01 от 28.09.2011 (переоформлено 26.12.2018).14.Бронхиальная астма. Федеральные клинические рекомендации Российского респираторного общества (РРО) 2019 г. (частота пересмотра каждые три года). http://spulmo.ru/obrazo-vatelnye-resursy/federalnye-klinicheskierekomendatsii/15.Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-36.16.Bousquet J, Boulet LP, Peters MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007; 101: 2437-46 (AHEAD).17.O’Byrne PM, FitzGerald JM, Bateman ED et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Eng J Med 2018; 378: 1865-76.18.Bateman ED, Reddel HK, O’Byrne PM et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med 2018; 378 (20): 1877-87.19.Beasley R, Holliday M, Reddel HK et al. Novel START Study Team. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. N Engl J Med 2019; 380 (21): 2020-30.20.Clinical study report. Study BFS-AS-306. Data on file. TEVA Pharmaceuticals, Inc. 2014.21.Weisfeld L, Shu Y, Shah TP. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohal er® (with and without charcoal block) in healthy volunteers. Int J Clin Pharmacol Ther 2015; 53 (7): 593-602.22.Pechere JC, Cenedese C, Muller O et al. Attitudinal classification of patients receiving antibiotic treatment for mild respiratory tract infections. Int J Antimicrob Agents 2002; 20 (6): 399-406.23.Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130 (1): 65S-72S.24.Laitinen LA, Laitinen A, Haahtela T A comparative study of the effects of an inhaled corticosteroid, bu-desonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90 (1): 32-42.25.Derendorf H. Nave R, Drollmann A et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28 (5): 1042-50.26.Tattersfield AE, Postma DS, Barnes PJ et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160 (2): 594-9.27.Stallberg B, Naya I, Ekelund J et al. Real-life use of budesonide/formoterol in clinical practice: a 12month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther 2015; 53 (6): 447-55.28.Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000; 94 (6): 607-11.29.Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001; 163 (1): 32-6.30.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet Respir Med 2017; 390: 1211-59.31.Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-44.32.Hermosa JL, Sanchez CB, Rubio MC et al. Factors associated with the control of severe asthma. J Asthma 2010; 47: 124-30.33.Ramsahai JM, Hansbro PM, Wark PAB. Mechanisms and Management of Asthma Exacerbations. Am J Respir Crit Care Med 2019; 199 (4): 423-32.34.O’Byrne P Fabbri LM, Pavord ID et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J 2019; 54 (1): 1900491.35.Global Strategy for Asthma Management and Prevention. 2020 GINA update Main Report, https://gi-nasthma.org/wpcontent/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf36.Федеральные клинические рекомендации по диагностике и лечению Бронхиальной астмы-2020. Российское респираторное общество. http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/37.Royal College of Physicians. Why Asthma Still Kills? The National Review of Asthma Deaths (NRAD) [online] 2014. 06.09.2018. https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills38.Papi A, Braithwaite I, Ebmeier S et al. Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma. Eur Respir J, 2020; 2003064. DOI: 10.1183/13993003.03064-202039.Stanford RH, Shah MB, D'Souza AO et al. Short-acting p-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol 2012; 109: 403-7.40.Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-6.41.Loymans RJB, Gemperli A, Cohen J et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 2014; 348: g3009.42.Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Согласованные рекомендации по применению режима единого ингалятора фиксированной комбинации будесонид/формотерол (SMART) в терапии пациентов с бронхиальной астмой. Практ. пульмонология. 2016; 1: 2-15.43.Vogelmeier C, D'Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26 (5): 819-28.44.Sears MR, Radner F Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009; 103 (12): 1960-8.45.Lee H, Ryu J, Nam E et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J 2019; 54 (5): 1900804.46.Holguin F, Cardet JC, Chung KF et al. Management of severe asthma: a European Respiratory So-ciety/American Thoracic Society guideline. Eur Respir J 2020; 55 (1): 1900588.47.Global Initiative for Asthma. Pocket guide 2019. https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf48.GINA Pocket Guide, “Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. V2.0. April 2019. https://ginasthma.org/severeasthma/49.Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139 (5 Pt 1): 359-70.50.Инструкция по медицинскому применению препарата ДуоРесп Спиромакс. http://grls.rosminz-drav.ru51.Авдеев С.Н., Белевский А.С., Айсанов З.Р. Новые подходы и алгоритм ведения пациентов с бронхиальной астмой. Практ. пульмонология. 2019; 1. https://cyberleninka.ru/article/n/novye-podhody-i-algoritm-vedeniya-patsientov-s-bronhialnoy-astmoy52.Diamant Z, Hanania NA. Generic medications in precision medicine in asthma. Curr Opin Pulm Med 2017; 23 (1): 1-2.53.Lavorini F, Ninane V, Haughney J et al. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin Drug Deliv 2013; 10 (12): 1597-602.54.Ekberg-Jansson A, Svenningsson I, Ragdell P et al. Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE). Int J Clin Pract 2015; 69 (10): 1171-8.55.Azouz W, Chetcuti P, Hosker H et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax* and Turbuhaler* devices: a randomised, cross-over study. BMC Pulm Med 2015; 15: 47.56.Chrystyn H, Dekhuijzen R, Rand C et al. P154. Evaluation of inhaler technique mastery for Budesonide Formoterol Spiromax* compared with Symbicort Turbohaler® in adult patients with asthma primary results from the Easy Low Instruction Over Time [ELIOT] study. Thorax 2015; 70: A154-5.57.Virchow JC, Rodriguez-Roisin R, Papi A et al. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax* compared to budesonide-formoterol Turbu-haler* in adults and adolescents with persistent asthma. BMC Pulm Med 2016; 16: 42.58.Voorham J, Roche N, Benhaddi H et al. Real-world effectiveness evaluation of budesonide/formo-terol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open 2018; 8 (10): e022051.59.Kew KM, Quinn M, Quon BS et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2016; 6: CD007524.60.Oborne J, Mortimer K, Hubbard RB et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009; 180 (7): 598-602.61.Valero A, Olaguibel J, Delgado J et al. Dilemmas and New Paradigms in Asthma Management. J Investig Allergol Clin Immunol 2019; 29 (1): 15-23.62.Price D, Chrystyn H, Kaplan A et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012; 4 (4): 184-91.63.Loukil M, Mejri I, Khalfallah I et al. Evaluation of inhaler techniques in patients with asthma and chronic obstructive disease. Rev Pneumol Clin 2018; 74 (4): 226-34.64.Chrystyn H, Safioti G, Keegstra JR et al. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. Int J Pharm 2015; 491 (1 -2): 268-76.